305 related articles for article (PubMed ID: 25797560)
21. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
22. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
23. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.
Strati P; Abruzzo LV; Wierda WG; O'Brien S; Ferrajoli A; Keating MJ
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):420-7. PubMed ID: 25800543
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
25. High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia.
Kristensen L; Kristensen T; Abildgaard N; Thomassen M; Frederiksen M; Mourits-Andersen T; Møller MB
Leuk Res; 2015 Jun; 39(6):555-60. PubMed ID: 25840748
[TBL] [Abstract][Full Text] [Related]
26. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Hing ZA; Mantel R; Beckwith KA; Guinn D; Williams E; Smith LL; Williams K; Johnson AJ; Lehman AM; Byrd JC; Woyach JA; Lapalombella R
Blood; 2015 May; 125(20):3128-32. PubMed ID: 25838351
[TBL] [Abstract][Full Text] [Related]
27. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
Karuturi M; Younes A; Fayad L; Kwak L; Pro B; Shah J; Oki Y; Simien R; Liboon MJ; Hutto T; Feng L; Horowitz S; Nieto Y; Anderlini P; Alousi A; Popat U; Medeiros LJ; Miranda R; Fanale M
Leuk Lymphoma; 2016 Feb; 57(2):445-447. PubMed ID: 25804933
[No Abstract] [Full Text] [Related]
29. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
30. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
31. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
33. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
34. Rituximab for treating inhibitors in people with inherited severe hemophilia.
Liu Y; Zhang L; Santoro C; Song J; Rodriguez A; Wang L
Cochrane Database Syst Rev; 2015 Apr; (4):CD010810. PubMed ID: 25841099
[TBL] [Abstract][Full Text] [Related]
35. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
Yeh YY; Ozer HG; Lehman AM; Maddocks K; Yu L; Johnson AJ; Byrd JC
Blood; 2015 May; 125(21):3297-305. PubMed ID: 25833959
[TBL] [Abstract][Full Text] [Related]
36. The epigenetic basis of diffuse large B-cell lymphoma.
Jiang Y; Melnick A
Semin Hematol; 2015 Apr; 52(2):86-96. PubMed ID: 25805588
[TBL] [Abstract][Full Text] [Related]
37. Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes.
Langerbeins P; Maurer C; Cramer P; Eichhorst B; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1575-6. PubMed ID: 25804766
[No Abstract] [Full Text] [Related]
38. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
Dybkær K; Bøgsted M; Falgreen S; Bødker JS; Kjeldsen MK; Schmitz A; Bilgrau AE; Xu-Monette ZY; Li L; Bergkvist KS; Laursen MB; Rodrigo-Domingo M; Marques SC; Rasmussen SB; Nyegaard M; Gaihede M; Møller MB; Samworth RJ; Shah RD; Johansen P; El-Galaly TC; Young KH; Johnsen HE
J Clin Oncol; 2015 Apr; 33(12):1379-88. PubMed ID: 25800755
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
40. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development.
Smith EN; Ghia EM; DeBoever CM; Rassenti LZ; Jepsen K; Yoon KA; Matsui H; Rozenzhak S; Alakus H; Shepard PJ; Dai Y; Khosroheidari M; Bina M; Gunderson KL; Messer K; Muthuswamy L; Hudson TJ; Harismendy O; Barrett CL; Jamieson CH; Carson DA; Kipps TJ; Frazer KA
Blood Cancer J; 2015 Apr; 5(4):e303. PubMed ID: 25860294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
